Oncology and Hematology

Episodes 65-80 of 92

Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Insights from global key opinion leaders on optimizing patient care in NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
1.00 credit 10 episodes
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 credit 10 episodes
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
MinuteCE®
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CE
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
0.25 credits
- Caroline Piatek, MD
- Irina Murakhovskaya, MD
0.25 credits
Risk-Stratification in Newly Diagnosed CLL
Risk-Stratification in Newly Diagnosed CLL
MinuteCE®
Risk-Stratification in Newly Diagnosed CLL
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
MinuteCE®
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
Combination Therapy for CLL: What Evidence Do We Have?
Combination Therapy for CLL: What Evidence Do We Have?
MinuteCE®
Combination Therapy for CLL: What Evidence Do We Have?
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
MinuteCE®
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits

5/6

Episodes 65-80 of 92

Title

Share on ReachMD